Last updated: 2026-09-16 10:32:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Allarity Therapeutics, Inc. (ALLR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.20, with a market capitalisation of $18.62M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.77 to $1.84. This page covers its latest market performance, valuation, price trends and company information.
$18.62M | |
$1.13 | |
$15,288,000.00 | |
$0.61 | |
$1.11 | |
2.79K | |
102.57K | |
-- | |
$1.84 | |
$0.77 | |
-- | |
-- |
Allarity Therapeutics, Inc. (ALLR) is trading at $1.20 in pre-market trading as of 2026-09-16 10:25:00, up 8.11% ($0.09) from the previous close of $1.11
Pre-market trading shows how investors are pricing ALLR before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Allarity Therapeutics, Inc. (ALLR) moved from $1.42 to $1.20, representing a decline of 15.49% ($0.22).
The stock traded between $1.09 and $1.45 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 131.43 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 40.3%
ALLR is currently trading at $1.20, placing it 40.3% of the way from its 52-week low of $0.77 to its 52-week high of $1.84. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 8 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Allarity Therapeutics, Inc. (ALLR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.